<DOC>
	<DOC>NCT00120055</DOC>
	<brief_summary>The aim of this study is to investigate whether the pharmacokinetics of atorvastatin and/or its metabolites is altered in patients with confirmed atorvastatin-induced myopathy compared to healthy controls.</brief_summary>
	<brief_title>Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity</brief_title>
	<detailed_description>A 24 hour pharmacokinetic investigation of atorvastatin and metabolites will be performed in 15 patients with a history of atorvastatin -induced myotoxicity. The possible link to relevant mutations in SLCO1B1, CYP3A5 and MDR1 will be also be investigated</detailed_description>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>above 18 years previous history of atorvastatinassociated myotoxicity current treatment with drugs or herbal remedies with known pharmacokinetic interaction potential with atorvastatin previous CK levels above ten times the upper limit of normal range pregnancy and persistent muscular complaints after a four week washout period of statin treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>